Anivive Secures Funding for Promising Valley Fever Vaccine
NIAID Awards Contract to Advance Vaccine Development
Long Beach, California, August 2, 2024 – Anivive Lifesciences Inc., a One Health technology company, announced today that it has received a contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to advance the development of a novel Valley Fever vaccine.
The Need for a Valley Fever Vaccine
Valley Fever is a serious respiratory infection caused by the fungus Coccidioides. It is prevalent in the southwestern United States and parts of Mexico and can lead to severe illness, including pneumonia and disseminated disease. Despite the high incidence of Valley Fever, there is currently no approved vaccine to prevent it.
Anivive's Vaccine Development
Anivive's vaccine leverages its proprietary One Health platform, which seamlessly integrates human and animal health expertise. The vaccine is designed to protect both humans and animals against Valley Fever and has shown promising results in preclinical studies.
This new contract from NIAID will provide critical funding to advance the vaccine into Phase 2 clinical trials, bringing it closer to the market. The trial will assess the safety and efficacy of the vaccine in humans, as well as its potential to prevent or reduce the severity of Valley Fever infection.
Dr. Arnab Gupta, Chief Medical Officer of Anivive, said, "We are thrilled to have received this support from NIAID. This contract validates the potential of our Valley Fever vaccine and will enable us to accelerate its development, bringing us closer to providing a much-needed solution to this devastating disease."
Comments